ATHX.Q Stock Overview
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Athersys, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.004 |
| 52 Week High | US$1.14 |
| 52 Week Low | US$0.0018 |
| Beta | -1.16 |
| 1 Month Change | -25.23% |
| 3 Month Change | -83.05% |
| 1 Year Change | -99.61% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Athersys: Is Big Pharma Sleeping At The Wheel?
Oct 06Athersys extends exercise period of warrants in connection with recent offering
Sep 23Athersys announces 1-for-25 reverse stock split
Aug 25One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher
Aug 16
Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents
Aug 12Kasey Rosado named interim CFO of Athersys
Aug 04Athersys: Dead Man Walking
Jul 25Athersys: Focus On Stroke
May 04Athersys - Hero Or Zero Opportunity
Apr 18Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
Jan 20Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely
Dec 30Athersys: COVID-ARDS Is The Company's Most Important Target
Nov 25Athersys Shares Are Ready To Rumble Following Period Of Turmoil
Aug 30Athersys: Subgroup Analysis As A Masterstroke
Jul 29Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation
May 28Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?
Feb 27Update On Athersys - Trying To Read Between The Lines
Feb 03Athersys: Risky Financial Position, But Promising Upside By FYE 2023
Feb 01Athersys: Stem Cell Opportunity For Risk Tolerant Investors
Nov 12Shareholder Returns
| ATHX.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -20.0% | -4.2% | -3.7% |
| 1Y | -99.6% | -2.0% | 20.5% |
Return vs Industry: ATHX.Q underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ATHX.Q underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ATHX.Q volatility | |
|---|---|
| ATHX.Q Average Weekly Movement | 43.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATHX.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ATHX.Q's weekly volatility (43%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 24 | n/a | www.athersys.com |
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications.
Athersys, Inc. Fundamentals Summary
| ATHX.Q fundamental statistics | |
|---|---|
| Market cap | US$253.17k |
| Earnings (TTM) | -US$37.51m |
| Revenue (TTM) | US$80.00k |
3.1x
P/S Ratio0.0x
P/E RatioIs ATHX.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATHX.Q income statement (TTM) | |
|---|---|
| Revenue | US$80.00k |
| Cost of Revenue | US$18.78m |
| Gross Profit | -US$18.69m |
| Other Expenses | US$18.81m |
| Earnings | -US$37.51m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | -23,368.75% |
| Net Profit Margin | -46,883.75% |
| Debt/Equity Ratio | -29.6% |
How did ATHX.Q perform over the long term?
See historical performance and comparison